Scholtz & Company’s Abbott ABT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.5M Sell
43,877
-5,320
-11% -$601K 2.31% 16
2025
Q4
$6.16M Buy
49,197
+1,150
+2% +$147K 2.68% 12
2025
Q3
$6.44M Buy
48,047
+1,414
+3% +$186K 2.83% 11
2025
Q2
$6.34M Sell
46,633
-735
-2% -$96.9K 2.78% 11
2025
Q1
$6.28M Sell
47,368
-93
-0.2% -$11.8K 3.11% 11
2024
Q4
$5.37M Buy
47,461
+5,902
+14% +$682K 2.56% 14
2024
Q3
$4.74M Buy
41,559
+903
+2% +$99K 2.24% 16
2024
Q2
$4.22M Buy
40,656
+33,624
+478% +$3.57M 1.8% 22
2024
Q1
$799K Sell
7,032
-7,885
-53% -$904K 0.35% 34
2023
Q4
$1.64M Sell
14,917
-19,716
-57% -$1.97M 0.81% 34
2023
Q3
$3.35M Sell
34,633
-3,216
-8% -$338K 2.21% 18
2023
Q2
$4.13M Sell
37,849
-1,326
-3% -$141K 2.58% 14
2023
Q1
$3.97M Sell
39,175
-560
-1% -$59.1K 2.83% 15
2022
Q4
$4.36M Sell
39,735
-995
-2% -$103K 3.09% 12
2022
Q3
$4.24M Sell
40,730
-13,336
-25% -$1.42M 3.03% 11
2022
Q2
$5.87M Sell
54,066
-3,115
-5% -$354K 3.61% 8
2022
Q1
$6.77M Buy
57,181
+456
+0.8% +$56.5K 2.67% 11
2021
Q4
$7.98M Sell
56,725
-18,190
-24% -$2.33M 2.58% 12
2021
Q3
$8.85M Sell
74,915
-10,070
-12% -$1.24M 3.13% 7
2021
Q2
$9.85M Buy
84,985
+2,035
+2% +$237K 3.37% 6
2021
Q1
$9.94M Buy
82,950
+2,342
+3% +$277K 3.78% 6
2020
Q4
$8.83M Sell
80,608
-4,236
-5% -$460K 3.45% 6
2020
Q3
$9.23M Buy
84,844
+300
+0.4% +$30.4K 4.03% 6
2020
Q2
$7.73M Buy
84,544
+1,254
+2% +$113K 3.86% 6
2020
Q1
$6.57M Buy
83,290
+8,995
+12% +$751K 5.03% 5
2019
Q4
$6.45M Buy
74,295
+2,475
+3% +$207K 3.75% 7
2019
Q3
$6.01M Buy
71,820
+46
+0.1% +$3.91K 4.01% 7
2019
Q2
$6.04M Buy
71,774
+5,085
+8% +$400K 3.91% 7
2019
Q1
$5.33M Buy
66,689
+792
+1% +$58.9K 3.55% 10
2018
Q4
$4.77M Buy
65,897
+10,087
+18% +$709K 4.14% 10
2018
Q3
$4.09M Buy
+55,810
New +$3.66M 2.58% 16

Other funds holding ABT

Scholtz & Company's ABT Position: Q1 2026 in Review

Scholtz & Company reduced its Abbott (ABT) stake by 11% in Q1 2026, selling an estimated $601K and leaving 43,877 shares worth $4.5M. The position accounts for 2.31% of the portfolio, ranked #16.

Scholtz & Company first reported a position in ABT in Q3 2018 and has held it in 31 quarters since. The position peaked at $9.94M in Q1 2021. 3,083 funds tracked by Wall St. Rank hold ABT as of Q1 2026.

  • Scholtz & Company held 43,877 shares of Abbott worth $4.5M as of Q1 2026.
  • Scholtz & Company sold 5,320 Abbott shares in Q1 2026, an estimated $601K.
  • Abbott made up 2.31% of Scholtz & Company's portfolio in Q1 2026, its #16 holding.
  • Scholtz & Company first reported a position in Abbott in Q3 2018 and has held it in 31 quarters since.
  • Scholtz & Company's Abbott position peaked at $9.94M in Q1 2021.
  • 3,083 funds tracked by Wall St. Rank held Abbott as of Q1 2026.

Based on Scholtz & Company's 13F filing for Q1 2026, filed 15 May 2026.